Unique ID issued by UMIN | UMIN000012853 |
---|---|
Receipt number | R000015020 |
Scientific Title | Phase 1 study of TM5509 -placebo controlled single dose study in male healthy adult subjects (high doses)- |
Date of disclosure of the study information | 2014/02/13 |
Last modified on | 2014/11/03 10:16:08 |
Phase 1 study of TM5509
-placebo controlled single dose study in male healthy adult subjects (high doses)-
placebo controlled single dose study in male healthy adult subjects (high doses) (TM5509-1)
Phase 1 study of TM5509
-placebo controlled single dose study in male healthy adult subjects (high doses)-
placebo controlled single dose study in male healthy adult subjects (high doses) (TM5509-1)
Japan |
Recover of hematogenesis after cord blood transplantation
Hematology and clinical oncology |
Others
YES
Investigation for safety of TM5509 in Japanese male healthy adult subjects.
Investigation for pharmacokinetics and pharmacodynamics of TM5509.
Safety
Exploratory
Safety of TM5509
Pharmacokinetics and pharmacodynamics of TM5509
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Treatment
Medicine |
TM5509
placebo
20 | years-old | <= |
45 | years-old | > |
Male
1. Male Japanese
2. From 20 years old to 45 years old at voluntary written consent
3. From 50.0 kg to 85.0 kg and from 18.5 to 25.0 of BMI at screening
4. Voluntary written consent by themselves is given before screening.
1. History of liver diseases, cardiovascular diseases, respiratory diseaases, gastroenteric diseases, kidney diseases, cerebralvascular diseases, cancer
2. Known hypersensitivity to some drugs and foods
3. Treatment by other doctors (included supplement) within 14 days before screening
4. Treatment with any investigational compound within 120 days before screening
5. History of TM5509 administration
6. History of blood taken
*>= 1200ml of all blood within 1 year before screening
*>= 400ml of all blood with 84 days before screening
*>= 200ml of all blood within 14 days before screening
7. Smoking status and treatment with anti-nicotine agents
8. Known active chronic hepatitis B or C, active syphilis and human immunodeficiency virus infection
9. Abuse of alcohol or drugs (included past history)
10. Bleeding, in the tendency to bleeding, and family history and past history of bleeding disorders
11. Somebody who are directed by principle investigator and employees in Hamamatsu University hospital
12. Any serious medical or psychiatric illness that could, in the opinion of the investigator, potentially interfere with the completion of treatment according to this protocol.
38
1st name | |
Middle name | |
Last name | Kazuo Umemura |
Hamamatsu University Hospital
Center for Clinical Research
Handayama 1-20-1, Higashi-ku, Hamamatsu
053-435-2006
umemura@hama-med.ac.jp
1st name | |
Middle name | |
Last name | kazuo umemua |
Hamamatsu University Hospital
Center for Clinical Research
Handayama 1-20-1, Higashi-ku, Hamamatsu
053-435-2006
http://www2.hama-med.ac.jp/w6a/trial/index.html
umemura@hama-med.ac.jp
Tohoku university school of medicine, molecular medicine and therapy, Toshio Miyata
ministry of education, culture, sports, science and technology
Japan
NO
浜松医大附属病院(静岡県)
2014 | Year | 02 | Month | 13 | Day |
Unpublished
Completed
2014 | Year | 02 | Month | 06 | Day |
2014 | Year | 02 | Month | 13 | Day |
2014 | Year | 08 | Month | 31 | Day |
2014 | Year | 08 | Month | 31 | Day |
2014 | Year | 11 | Month | 30 | Day |
2014 | Year | 11 | Month | 30 | Day |
2014 | Year | 01 | Month | 15 | Day |
2014 | Year | 11 | Month | 03 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015020
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |